Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
news
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
South San Francisco, California, January 12, 2007 - The Company provides below details of changes in the interests of Directors, Persons Discharging Managerial Responsibility or Connected Persons in the Ordinary Shares of Napo Pharmaceuticals, Inc.
The following persons were granted options over an aggregate of 600,000 Ordinary Shares in the Company in the Napo Pharmaceuticals, Inc. 2006 Equity Incentive Plan
| Name | Role | Number of Options | Grant Price | Vesting |
| Mr. James Nash | Chief Operating Officer | 500,000 | 94.5 pence | 300,000 over 12 months from achievement of certain milestones, 200,000 from Jan 15/07 vesting over 36 months |
| Mr. Mustapha Leavenworth Bakali | Non-Executive Director | 100,000 | 94.5 pence | Vest 12 months from appointment 10 Jan, 07 |
This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R
For more information please contact:
Napo Pharmaceuticals, Inc.
Lisa Conte, Chief Executive Officer
+1 (650) 616-1902
Charles Thompson, Chief Financial Officer
+1 (650) 616-1903
Buchanan Communications
+ 44 (0)20 7466 5000
Tim Anderson, Mary-Jane Johnson
Nomura Code Securities Limited
+44 (0)20 7776 1204
Juliet Thompson
About Napo
Napo Pharmaceuticals Inc., focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. Napo was founded in November 2001, and is based in California, USA with a subsidiary in Mumbai, India.
Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in various stages of clinical development for four distinct product indications, including a late-stage Phase 3 program:
- CRO-HIV for AIDS diarrhea, Phase 3
- CRO-IBS for diarrhea irritable bowel syndrome (D-IBS), Phase 2
- CRO-ID for acute infectious diarrhea (including cholera), Phase 2
- CRO-PED for pediatric diarrhea, Phase 1
The FDA has granted fast-track status to CRO-IBS and CRO-HIV. Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Napo also plans to develop an early clinical stage product, NP-500, for the treatment of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions and Napo has entered its first screening relationship associated with this collection. Currently, products are based on the chemical and biological diversity derived from plants with medicinal properties, but future products may be in-licensed from other sources. Napo has partnerships with Trine Pharmaceuticals, Inc. of the United States of America; Glenmark Pharmaceuticals Limited of India; and AsiaPharm Group Ltd. of China. For more information please visit www.napopharma.com